METASTATIC GASTRIC CANCER
Clinical trials for METASTATIC GASTRIC CANCER explained in plain language.
Never miss a new study
Get alerted when new METASTATIC GASTRIC CANCER trials appear
Sign up with your email to follow new studies for METASTATIC GASTRIC CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug hopes to shrink advanced tumors in early trial
Disease control Recruiting nowThis early-phase study tests a new drug called IPH5301 in people with advanced solid tumors that have spread. The drug works by blocking a protein (CD73) that tumors use to hide from the immune system. The study first finds the safest dose of IPH5301 alone, then tests it combined…
Matched conditions: METASTATIC GASTRIC CANCER
Phase: PHASE1 • Sponsor: Institut Paoli-Calmettes • Aim: Disease control
Last updated May 16, 2026 22:33 UTC
-
New immune cocktail targets tough stomach cancers
Disease control Recruiting nowThis study tests a mix of immune cells (agenT-797) and three immunotherapy drugs (botensilimab, balstilimab, ramucirumab) plus chemotherapy (paclitaxel) for people with advanced stomach, esophageal, or gastro-esophageal junction cancer that has worsened after one prior treatment.…
Matched conditions: METASTATIC GASTRIC CANCER
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
New drug cocktail targets Hard-to-Treat HER2 cancers
Disease control Recruiting nowThis study tests a combination of two drugs—disitamab vedotin and tucatinib—for people with advanced breast or stomach cancers that have a protein called HER2. The goal is to see if the combo is safe and can shrink or control tumors. About 172 adults with these cancers who have a…
Matched conditions: METASTATIC GASTRIC CANCER
Phase: PHASE2 • Sponsor: Seagen, a wholly owned subsidiary of Pfizer • Aim: Disease control
Last updated May 13, 2026 16:03 UTC
-
New pill targets Hard-to-Treat cancers in early human trial
Disease control Recruiting nowThis early-phase study tests an experimental pill, NKT3964, designed to break down a protein (CDK2) that helps cancer cells grow. About 150 adults with advanced or metastatic solid tumors (including ovarian, endometrial, breast, gastric, and lung cancers) that have stopped respon…
Matched conditions: METASTATIC GASTRIC CANCER
Phase: PHASE1 • Sponsor: NiKang Therapeutics, Inc. • Aim: Disease control
Last updated May 13, 2026 16:01 UTC
-
Promising new combo tackles advanced stomach cancer in early trial
Disease control Recruiting nowThis study tests a new drug combination (iparomlimab and tuvonralimab, called QL1706) plus chemotherapy in people with advanced stomach or gastroesophageal junction cancer that hasn't been treated yet. The goal is to see if the combination shrinks tumors and is safe. About 32 par…
Matched conditions: METASTATIC GASTRIC CANCER
Phase: PHASE2 • Sponsor: Beijing Friendship Hospital • Aim: Disease control
Last updated May 11, 2026 20:54 UTC
-
New hope for stomach cancer: drug combo trial launches
Disease control Recruiting nowThis study tests a new drug called SHR2554 combined with other cancer treatments for people with advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery or has spread. The goal is to see if the combination is safe and helps shrink tumors. About 351 …
Matched conditions: METASTATIC GASTRIC CANCER
Phase: PHASE2 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Disease control
Last updated May 11, 2026 20:52 UTC
-
New combo therapy aims to fight Hard-to-Treat stomach cancers
Disease control Recruiting nowThis study tests a new medicine (PF-08634404) combined with chemotherapy for people with advanced stomach, gastroesophageal junction, or esophageal cancer that has not been treated before. The trial has two parts: first checking safety and response, then comparing the new combo t…
Matched conditions: METASTATIC GASTRIC CANCER
Phase: PHASE2, PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated May 11, 2026 20:40 UTC
-
Could a longer chemo infusion help patients with low muscle mass?
Knowledge-focused Recruiting nowThis study looks at whether giving a longer infusion of the chemotherapy drug paclitaxel to cancer patients with low muscle mass can make drug levels in their blood more like those in patients with normal muscle mass. About 22 women with breast, stomach, or esophageal cancer will…
Matched conditions: METASTATIC GASTRIC CANCER
Phase: PHASE4 • Sponsor: University of Michigan Rogel Cancer Center • Aim: Knowledge-focused
Last updated May 16, 2026 22:33 UTC